1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014

Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Renal Cell Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Metastatic Renal Cell Carcinoma 9
Report Guidance 9
Clinical Trials by Region 10
Clinical Trials and Average Enrollment by Country 11
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13
Top Five Countries Contributing to Clinical Trials in Europe 14
Top Countries Contributing to Clinical Trials in North America 15
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 16
Top Five Countries Contributing to Clinical Trials in Central and South America 17
Clinical Trials by G7 Countries: Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials 18
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials 21
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 27
Unaccomplished Trials of Metastatic Renal Cell Carcinoma 28
Subjects Recruited Over a Period of Time 34
Clinical Trials by Sponsor Type 35
Prominent Sponsors 36
Top Companies Participating in Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials 37
Prominent Drugs 39
Latest Clinical Trials News on Metastatic Renal Cell Carcinoma 40
Jan 14, 2014: Rexahn Initiates Phase IIa Clinical Trial of Archexin in Patients with Metastatic Renal Cell Carcinoma 40
Dec 19, 2013: NewLink Genetics Launches Phase 1 Clinical Trial of Its HyperAcute Renal Immunotherapy in Patients With Metastatic Renal Cell Cancer 41
Oct 22, 2013: Curis and Debiopharm Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus 41
Sep 24, 2013: Argos Therapeutics Announces Globalization of Pivotal Phase 3 ADAPT Study for Personalized Cancer Immunotherapy 42
Sep 23, 2013: TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients With Metastatic Renal Cell Carcinoma 43
Clinical Trial Profiles 44
Clinical Trial Overview of Top Companies 44
Pfizer Inc. 44
Clinical Trial Overview of Pfizer Inc. 44
Novartis AG 48
Clinical Trial Overview of Novartis AG 48
Bayer AG 51
Clinical Trial Overview of Bayer AG 51
F. Hoffmann-La Roche Ltd. 53
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 53
GlaxoSmithKline plc 55
Clinical Trial Overview of GlaxoSmithKline plc 55
Bristol-Myers Squibb Company 57
Clinical Trial Overview of Bristol-Myers Squibb Company 57
AstraZeneca PLC 58
Clinical Trial Overview of AstraZeneca PLC 58
Eli Lilly and Company 59
Clinical Trial Overview of Eli Lilly and Company 59
iOMEDICO AG 60
Clinical Trial Overview of iOMEDICO AG 60
Amgen Inc. 61
Clinical Trial Overview of Amgen Inc. 61
Clinical Trial Overview of Top Institutes / Government 62
National Cancer Institute 62
Clinical Trial Overview of National Cancer Institute 62
The University of Texas M. D. Anderson Cancer Center 67
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 67
Memorial Sloan Kettering Cancer Center 68
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 68
The University of Chicago 69
Clinical Trial Overview of The University of Chicago 69
Case Comprehensive Cancer Center 70
Clinical Trial Overview of Case Comprehensive Cancer Center 70
UCLA's Jonsson Comprehensive Cancer Center 71
Clinical Trial Overview of UCLA's Jonsson Comprehensive Cancer Center 71
University of California, San Francisco 72
Clinical Trial Overview of University of California, San Francisco 72
Radboud University 73
Clinical Trial Overview of Radboud University 73
European Organization for Research and Treatment of Cancer 74
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 74
Roswell Park Cancer Institute 75
Clinical Trial Overview of Roswell Park Cancer Institute 75
Five Key Clinical Profiles 76
Appendix 198
Abbreviations 198
Definitions 198
Research Methodology 199
Secondary Research 199
About GlobalData 200
Contact Us 200
Disclaimer 200
Source 201

List of Tables
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2014* 10
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 11
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 12
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 13
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 14
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 15
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 16
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 17
Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2014* 18
Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 19
Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 20
Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2014* 21
Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 22
Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 23
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2014* 24
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 25
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 26
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 27
Metastatic Renal Cell Carcinoma Therapeutics, Global, Suspended Clinical Trials, 2014* 28
Metastatic Renal Cell Carcinoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 29
Metastatic Renal Cell Carcinoma Therapeutics, Global, Terminated Clinical Trials, 2014* 30
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 34
Metastatic Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 35
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 36
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 38
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 39
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 44
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 48
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 51
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 53
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 55
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 57
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 58
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 59
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by iOMEDICO AG, 2014* 60
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 61
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 62
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 67
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 68
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 69
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 70
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by UCLA's Jonsson Comprehensive Cancer Center, 2014* 71
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 72
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2014* 73
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 74
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014* 75

List of Figures
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 10
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 11
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 12
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 13
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 14
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 15
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 16
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 17
Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2014* 18
Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 19
Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 20
Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2014* 21
Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 22
Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 23
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 24
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 25
Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 26
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 27
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 34
Metastatic Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 35
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 36
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 37
Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 39
GlobalData Methodology 199

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Renal Cancer: Analytical Tool

Renal Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Renal cell carcinoma- Market Insights, Epidemiology and Market Forecast-2023

Renal cell carcinoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Renal cell carcinoma - Epidemiology Forecast To 2023

Renal cell carcinoma - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Renal cell carcinoma - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Renal cell carcinoma in seven major markets (US, France, Germany, Italy, Spain, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.